Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-31 @ 6:46 PM
Study NCT ID:
NCT02521051
Status:
TERMINATED
Last Update Posted:
2025-05-13
First Post:
2015-07-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Sponsor:
Massachusetts General Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-20
First Submit QC Date:
None
Study First Post Date:
2015-08-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-03-10
Results First Submit QC Date:
None
Results First Post Date:
2025-05-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-25
Last Update Post Date:
2025-05-13
Last Update Post Date Type:
ACTUAL